We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Gracell Biotechnologies Inc | NASDAQ:GRCL | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.25 | 10.25 | 10.00 | 0 | 01:00:00 |
From Dec 2023 to Jun 2024
By Colin Kellaher
American depositary share of Gracell Biotechnologies surged nearly 60% in premarket trading Tuesday after the clinical-stage biopharmaceutical company agreed to be acquired by pharmaceutical giant AstraZeneca in a deal worth up to $1.2 billion.
AstraZeneca is paying an initial $1 billion, or $10 an ADS, in cash for Gracell, a nearly 62% premium to Friday's closing price of $6.19 for the Shanghai-based company.
Gracell said its investors also will receive non-tradable contingent value rights tied to a future regulatory milestone that are worth up to $1.50 an ADS in cash, bringing the total potential deal value to $11.50 an ADS, about 86% above Friday's closing price.
Gracell ADSs were recently up 58% to $9.76 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 26, 2023 06:29 ET (11:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gracell Biotechnologies Chart |
1 Month Gracell Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
